Guobang Pharma (SHSE:605507) Long-Term Debt: ¥177 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:605507 Guobang Pharma Ltd SHSE:605507
83 GF Score
Price ¥15.58
GF Value ¥15.62
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Guobang Pharma Long-Term Debt?

Guobang Pharma SHSE:605507 -2.63% 83 Long-Term Debt is ¥177 Mil as of Jun. 2026. GuruFocus rates SHSE:605507 with a GF Score™ of 83/100 and a GF Value™ of ¥15.62 (Fairly Valued). The stock has 4 warning signs investors should review.

Guobang Pharma's Long-Term Debt for the quarter that ended in Jun. 2026 was ¥177 Mil.

Guobang Pharma's quarterly Long-Term Debt declined from Dec. 2025 (¥478 Mil) to Mar. 2026 (¥83 Mil) but then increased from Mar. 2026 (¥83 Mil) to Jun. 2026 (¥177 Mil).

Guobang Pharma's annual Long-Term Debt declined from Dec. 2023 (¥452 Mil) to Dec. 2024 (¥147 Mil) but then increased from Dec. 2024 (¥147 Mil) to Dec. 2025 (¥478 Mil).

Guobang Pharma  (SHSE:605507) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Guobang Pharma Long-Term Debt Related Terms

Guobang Pharma Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Guobang Pharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guobang Pharma Long-Term Debt Chart

Guobang Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 451.70 146.72 478.01

Guobang Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 507.00 478.71 478.01 82.88 176.57
SHSE:605507
83GF Score
Guobang Pharma Ltd SHSE:605507
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ¥177 Mil mean?
Guobang Pharma (SHSE:605507) has a Long-Term Debt of ¥177 Mil as of Jun. 2026.
Is Guobang Pharma's Long-Term Debt too high?
Guobang Pharma's current Long-Term Debt is ¥177 Mil. Overall, Guobang Pharma has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Guobang Pharma's Long-Term Debt compare to ZTS?
Guobang Pharma's Long-Term Debt of ¥177 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Guobang Pharma's current Long-Term Debt is ¥177 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guobang Pharma stock overvalued right now?
Based on GuruFocus' analysis, Guobang Pharma (SHSE:605507) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.62, compared to a current price of ¥15.58 — trading 0.3% below its estimated fair value. The current Long-Term Debt is ¥177 Mil. Guobang Pharma's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Guobang Pharma (SHSE:605507), the current Long-Term Debt is ¥177 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guobang Pharma (SHSE:605507) Overvalued in 2026?

Based on GuruFocus' analysis, Guobang Pharma stock appears to be undervalued. The current stock price of ¥15.58 is trading 0.3% below its estimated GF Value™ of ¥15.62. GuruFocus considers Guobang Pharma to be Fairly Valued.

Key valuation signals for SHSE:605507:

  • Long-Term Debt: ¥177 Mil
  • GF Value™: ¥15.62 vs. price of ¥15.58 (0.3% below fair value)
  • GF Score™: 83/100 with 4 warning signs

No single metric tells the full story. See the SHSE:605507 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Guobang Pharma Business Description

Address No. 60, Xingmei Avenue, Provincial High-tech Industrial Park, Zhejiang Province, Xinchang, CHN, 312500
Guobang Pharma Ltd is engaged in the research and development, production and sales of related products in the field of medicine and animal health products.
83GF Score

Get the complete analysis for SHSE:605507

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥15.58
Price
¥15.62
GF Value